GLP-1 Market
LLY $1381.18 ▼ -2.4% NVO $39.49 ▼ -3.0% PFE $28.07 ▼ -1.4% VKTX $26.19 ▼ -2.6% KLRA $11.89 ▼ -2.5% GPCR $17.36 ▼ -4.5% RHHBY $59.55 ▼ -1.2%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

QLS2406-1

QLS2406-1

Company
Shanghai Qilu Pharmaceutical Research and Development Center LTD
Mechanism
Mechanism not yet reported
Route
Injectable
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 18, 2026

Trial details
  • Not yet recruiting NCT NCT07937787

    A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.

    Not yet reported Shanghai Qilu Pharmaceutical Research and Development Center LTD 124 participants Est. completion 2028-03-30 Stand-alone
    MASH Other conditions: Overweight and Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: QLS2406-1, QLS2406-1 injection

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.